



Patent Docket P2000R1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Victoria Smith Serial No.: 10/712,124 Filed: November 13, 2003 For: Methods and Compositions for Detecting Dysplasia	Group Art Unit: 1645 Examiner: To Be Assigned Confirmation No: 7683 CUSTOMER NO: 09157 EXPRESS MAIL LABEL NO.: <u>EV385658641US</u> DATE OF DEPOSIT: <u>FEBRUARY 4, 2005</u>
--	---

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

(X) **37 CFR §1.97(b)**

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); **or**
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR §1.491, **or**
- before the mailing of the first Office action on the merits; **or**
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

0 **37 CFR §1.97(c)**

- by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set

forth in 37 CFR §1.17(p) or a statement as specified in 37 CFR §1.97(e), as checked below.

☐ **37 CFR §1.97(d)**

- after the period specified in CFR §1.97(c), and is accompanied by the fee set forth in 37 CFR §1.17(p) and a statement as specified in 37 CFR §1.97(e), as checked below.

(If either of boxes 37 CFR §1.97(c) or 37 CFR §1.97(d) is checked above, the following statement under 37 CFR §1.97(e) may need to be completed.)

- ☐ **37 CFR §1.97(e)** Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- ☐ **37 CFR §1.704(d)** Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- ☐ The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) and/or publication(s) is set forth on the attached revised Form PTO-1449.

A copy of the items on PTO-1449 is supplied herewith.

Those patent(s) or publication(s) which are marked with an asterisk (*) in the attached PTO-1449 form are not supplied because this application was filed after June 30, 2003. Applicants are no longer required to submit copies of U.S. patents and U.S. patent application publications cited in information disclosure statements for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC §371 after June 30, 2003 (**1276 OG 55**). Nevertheless, applicants stand ready to provide copies at the request of the Examiner.

A concise explanation of relevance of the items listed on PTO-1449 is:

- ☒ not given
- ☐ given for each listed item
- ☐ given for only non-English language listed item(s) (Required)
- ☐ in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR §1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630.

Respectfully submitted,

GENENTECH, INC.

Date: February 4, 2005

By: 

Deirdre L. Conley, Ph.D.

Reg. No. 36,487

Telephone No. (650) 225-2066

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P2000R1Serial No.
10/712,124

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant
Victoria SmithFiling Date
13 Nov 2003Group
1645

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

40	Huse et al., "Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda" <u>Science</u> 246:1275-1281 (1989)
41	Ilantzis et al., "Deregulated Expression of the Human Tumor Marker CEA and CEA Family Member CEACAM6 Disrupts Tissue Architecture and Blocks Colonocyte Differentiation" <u>Neoplasia</u> 4:151-163 (2002)
42	Kabat et al. <u>Sequences of Proteins of Immunological Interest</u> (NIH Publ. No. 91-3242) I:647-669 (1991)
43	Kawakami et al., "Hypermethylated APC DNA in Plasma and Prognosis of Patients With Esophageal Adenocarcinoma" <u>J. Natl. Cancer Institute</u> 92:1805-1811 (2000)
44	Kingston, "Preparation and Analysis of RNA" <u>Current Protocols in Molecular Biology</u> 1:4.2.5 - 4.2.6 (1991)
45	Kohler and Milstein., "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity." <u>Nature</u> . 256:495-497 (August 7, 1975)
46	Korinek et al., "Constitutive Transcriptional Activation by a β -Catenin-Tcf Complex in APC ^{-/-} Colon Carcinoma" <u>Science</u> 275:1784-1787 (1997)
47	Korinek et al., "Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4" <u>Nature Gen.</u> 19:379-383 (1998)
48	Kozbor et al., "Specific Immunoglobulin Production and Enhanced Tumorigenicity Following Ascites Growth of Human Hybridomas" <u>Immunol. Methods</u> 81:31-42 (1985)
49	Kumar et al., "Identification and Initial Characterization of Four Novel Members of the Interleukin-1 Family" <u>The Journal of Biological Chemistry</u> 275:10308-10314 (2000)
50	Lee, et al., "IL-17E, a Novel Proinflammatory Ligand for the IL-17 Receptor Homolog IL-17Rh1" <u>The Journal of Biological Chemistry</u> 276(2):1660-1664 (2001)
51	Lerut et al., "Surgical treatment of Barrett's carcinoma" <u>The Journal of Thoracic and Cardiovascular Surgery</u> 107:1059-1066 (1994)
52	Lescher et al., "sFRP-2 Is a Target of the Wnt-4 Signaling Pathway in the Developing Metanephric Kidney" <u>Developmental Dynamics</u> 213:440-451 (1998)
53	Liu et al., "Coexpression of Ephrin-Bs and their Receptors in Colon Carcinoma" <u>Cancer</u> 94:934-939 (2002)
54	Lu et al., "Molecular Basis for Feedback Regulation of Bile Acid Synthesis by Nuclear Receptors" <u>Molecular Cell</u> 6:507-515 (2000)
55	MacLennan et al., "Identification of Intestinal-Type Barrett's Metaplasia by Using the Intestine-Specific Protein Villin and Esophageal Brush Cytology" <u>Molecular Carcinogenesis</u> 24:137-143 (1999)
56	Marchenko et al., "Promoter characterization of the novel human matrix metalloproteinase-26 gene: regulation by the T-cell factor-4 implies specific expression of the gene in cancer cells of epithelial origin" <u>Biochemical Journal</u> 363:253-262 (2002)
57	Marks et al., "By-Passing Immunization: Human Antibodies From V-gene Libraries Displayed On Phage" <u>J. Mol. Biol.</u> 222:581-597 (1991)
58	Medina et al., "Human Colon Adenocarcinomas Express a MUC1-associated Novel Carbohydrate Epitope on Core Mucin Glycans Defined by a Monoclonal Antibody (A10) Raised against Murine Ehrlich Tumor Cells" <u>Cancer Research</u> 59:1061-1070 (1999)
59	Menke-Pluymers et al., "Outcome of surgical treatment of adenocarcinoma in Barrett's oesophagus" <u>Gut</u> 33:1454-1458 (1992)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P2000R1Serial No.
10/712,124

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant
Victoria SmithFiling Date
13 Nov 2003Group
1645

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
	* 1	4,675,187	23.06.87	Konishi et al.			
	* 2	4,816,567	28.03.89	Cabilly et al.			

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

	3	Aberger et al., "Anterior specification of embryonic ectoderm: the role of the <i>Xenopus</i> cement gland-specific gene XAG-2" <u>Mech. Dev.</u> 72:115-130 (1998)
	4	Al-Kassspooles et al., "Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas" <u>Internat. J. Cancer</u> 54:213-219 (1993)
	5	Alikhan et al., "Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice" <u>Gastrointest. Endosc.</u> 50:23-26 (1999)
	6	Altschul and Gish, "Local Alignment Statistics" <u>Methods in Enzymology</u> 266:460-480 (1996)
	7	Altschul et al., "Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs" <u>Nucleic Acids Research</u> . 25(17):3389-3402 (1997)
	8	Baba et al., "Identification of CCR6, the Specific Receptor for a Novel Lymphocyte-directed CC Chemokine LARC" <u>Journal of Biological Chemistry</u> 272:14893-14898 (1997)
	9	Bakin & Curran, "Role of DNA 5-Methylcytosine Transferase in Cell Transofrmation by fos" <u>Science</u> 283:387-390 (1999)
	10	Bani-Hani et al., "Prospective Study of Cyclin D1 Overexpression in Barrett's Esophagus: Association with Increased Risk of Adenocarcinoma" <u>J. Natl. Cancer Institute</u> 92:1316-1321 (2000)
	11	Barker et al., "Restricted High Level Expression of Tcf-4 Protein in Intestinal and Mammary Gland Epithelium" <u>Am. J. Pathol.</u> 154:29-35 (1999)
	12	Barrett et al., "Transcriptional Analyses of Barrett's Metaplasia and Normal Upper GI Mucosae" <u>Neoplasia</u> 4:121-128 (2002)
	13	Bjerknes & Cheng, "Modulation of specific intestinal epithelial progenitors by enteric neurons" <u>Proc. Natl. Acad. Sci. USA</u> 98:12497-12502 (2001)
	14	Bollschweiler et al., "Demographic Variations in the Rising Incidence of Esophageal Adenocarcinoma in White Males" <u>Cancer</u> 92:549-555 (2001)
	15	Bremner et al., "Barrett's esophagus: Congenital or acquired? An experimental study of esophageal mucosal regeneration in the dog" <u>Surgery</u> 68:209-216 (1970)
	16	Brummelkamp et al., "A System for Stable Expression of Short Interfering RNAs in Mammalian Cells" <u>Science</u> 296:550-553 (2002)
	17	Cameron & Carpenter, "Barrett's Esophagus, High-Grade Dysplasia, and Early Adenocarcinoma: A Pathological Study" <u>The American Journal of Gastroenterology</u> 92:586-591 (1997)
	18	Cameron & Lomboy, "Barrett's Esophagus: Age, Prevalence, and Extent of Columnar Epithelium" <u>Gastroenterology</u> 103:1241-1245 (1992)
	19	Cameron et al., "Prevalence of Columnar-Lined (Barrett's) Esophagus" <u>Gastroenterology</u> 99:918-922 (1990)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P2000R1	Serial No. 10/712,124
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Victoria Smith	
				Filing Date 13 Nov 2003	Group 1645
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
20	Cameron et al., "The incidence of adenocarcinoma in columnar-lined (barrett's) esophagus" <u>New Eng. J. Med.</u> 313:857-859 (1985)				
21	Chothia and Lesk, "Canonical Structures for the Hypervariable Regions of Immunoglobulins" <u>J. Mol. Biol.</u> 196:901-917 (1987)				
22	Ciardiello et al., "Differential expression of epidermal growth factor-related proteins in human colorectal tumors" <u>Proc. Natl. Acad. Sci. USA</u> 88:7792-7796 (1991)				
23	Clackson et al., "Making Antibody Fragments Using Phage Display Libraries" <u>Nature</u> 352:624-628 (1991)				
24	Cole et al., "Human monoclonal antibodies" <u>Mol. Cell Biol.</u> 62:109-120 (1984)				
25	Csendes et al., "Prevalence of Barrett's esophagus by endoscopy and histologic studies: a prospective evaluation of 306 control subjects and 376 patients with symptoms of gastroesophageal reflux" <u>Diseases of the Esophagus</u> 13:5-11 (2000)				
26	Devesa et al., "Changing Patterns in the Incidence of Esophageal and Gastric Carcinoma in the United States" <u>Cancer</u> 83:2049-2053 (1998)				
27	Di Toro et al., "Effects of specific bile acids on c-fos messenger RNA levels in human colon carcinoma Caco-2 cells" <u>Eur. J. Pharm. Sci.</u> 11:291-298 (2000)				
28	Drewitz et al., "The Incidence of Adenocarcinoma in Barrett's Esophagus: A Prospective Study of 170 Patients Followed 4.8 Years" <u>Amer. J. Gastroenterol</u> 92:212-215 (1997)				
29	Falk et al., "Barrett's Esophagus" <u>Gastroenterology</u> 122:1569-1591 (2002)				
30	Falk et al., "Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett's esophagus with high-grade dysplasia" <u>Gastrointest. Endosc.</u> 49:170-176 (1999)				
31	Gillen et al., "Experimental columnar metaplasia in the canine oesophagus" <u>Br. J. Surg.</u> 75:113-115 (1988)				
32	Gillen et al., "Implication of duodenogastric reflux in the pathogenesis of Barrett's oesophagus" <u>Br. J. Surg.</u> 75:540-543 (1988)				
33	Goetze et al., "TNF α induces expression of transcription factors c-fos, Egr-1, and Ets-1 in vascular lesions through extracellular signal-regulated kinases 1/2" <u>Atherosclerosis</u> 159:93-101 (2001)				
34	Goldman et al., "In vitro and in vivo gene delivery mediated by a synthetic polycationic amino polymer" <u>Nature Biotechnology</u> 15:462-466 (1997)				
35	Heasley et al., "Induction of Cytosolic Phospholipase A2 by Oncogenic Ras in Human Non-small Cell Lung Cancer" <u>Journal of Biological Chemistry</u> 272:14501-14504 (1997)				
36	Heller et al., "Discovery and analysis of inflammatory disease-related genes using cDNA microarrays" <u>Proc. Natl. Acad. Sci. USA</u> 94:2150-2155 (1997)				
37	Heller, M., "DNA Microarray Technology: Devices, Systems, and Applications" <u>Annual Review of Biomedical Engineering</u> 4:129-153 (2002)				
38	Hiltunen et al., "Hypermethylation of the APC (Adenomatous Polyposis Coli) Gene Promoter Region in Human Colorectal Carcinoma" <u>Int. J. Cancer</u> 70:644-648 (1997)				
39	Howe et al., "Transcriptional Activation of Cyclooxygenase-2 in Wnt-1-transformed Mouse Mammary Epithelial Cells" <u>Cancer Research</u> 59:1572-1577 (1999)				
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P2000R1Serial No.
10/712,124

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant
Victoria SmithFiling Date
13 Nov 2003Group
1645

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- | | |
|----|--|
| 60 | Miros et al., "Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus" <u>Gut</u> 32:1441-1446 (1991) |
| 61 | Miwa et al., "Involvement of Claudin-1 in the β -Catenin/Tcf Signaling Pathway and its Frequent Upregulation in Human Colorectal Cancers" <u>Oncology Research</u> 12:469-476 (2000) |
| 62 | Morris et al., "Cyclooxygenase-2 Expression in the Barrett's Metaplasia-Dysplasia-Adenocarcinoma Sequence" <u>Am. J. Gastroenterol.</u> 96:990-996 (2001) |
| 63 | Morrison et al., "Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains with Human Constant Region Domains" <u>Proc. Natl. Acad. Sci. USA</u> 81:6851-6855 (November 1984) |
| 64 | Muller et al., "Involvement of chemokine receptors in breast cancer metastasis" <u>Nature</u> 410:50-56 (2001) |
| 65 | Munz et al., "Overexpression of activin A in the skin of transgenic mice reveals new activities of activin in epidermal morphogenesis, dermal fibrosis and wound repair" <u>EMBO Journal</u> 18:5205-5215 (1999) |
| 66 | Murakami et al., "Cell Cycle Regulation, Oncogenes, and Antineoplastic Drugs" <u>The Molecular Basis of Cancer</u> , Mendelsohn and Israel, eds, Philadelphia:WB Saunders, Chapter 1, pps. 3-17 (1995) |
| 67 | Nielsen et al., "Identification of Prokaryotic and Eukaryotic Signal Peptides and Prediction of Their Cleavage Sites" <u>Protein Engineering</u> 10(1):1-6 (1997) |
| 68 | Node et al., "Anti-inflammatory Properties of Cytochrome P450 Epoxygenase-Derived Eicosanoids" <u>Science</u> 285:1276-1279 (1999) |
| 69 | O'Connor, "The Incidence of Adenocarcinoma and Dysplasia in Barrett's Esophagus" <u>Am. J. Gastroenterol.</u> 94:2037-2042 (1999) |
| 70 | Paddison et al., "Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells" <u>Genes & Development</u> 16:948-958 (2002) |
| 71 | Pai et al., "Prostaglandin E ₂ transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy" <u>Nature Med.</u> 8:289-293 (2002) |
| 72 | Peterson & Mooseker, "Characterization of the enterocyte-like brush border cytoskeleton of the C2BBe clones of the human intestinal cell line, Caco-2" <u>Journal of Cell Science</u> 102:581-600 (1992) |
| 73 | Romagnoli et al., "Molecular Alterations of Barrett's Esophagus on Microdissected Endoscopic Biopsies" <u>Laboratory Investigation</u> 81:241-247 (2001) |
| 74 | Rys-Sikora et al., "Coordinate expression of secretory phospholipase A2 and cyclooxygenase-2 in activated human keratinocytes" <u>Am J Physiol Cell Physiol</u> 278:C822-C833 (2000) |
| 75 | Sagara et al., "Molecular Cloning, Differential Expression, and Chromosomal Localization of Human Frizzled-1, Frizzled-2, and Frizzled-7" <u>Biochem. and Biophysics. Res. Comm.</u> 252:117-122 (1998) |
| 76 | Sampliner et al., "Practice Guidelines on the Diagnosis, Surveillance, and Therapy of Barrett's Esophagus" <u>Am. J. Gastroenterol.</u> 93:1028-1032 (1998) |
| 77 | Sarr et al., "Barrett's Esophagus: Its Prevalence and Association With Adenocarcinoma In Patients With Symptoms of Gastroesophageal Reflux" <u>The American Journal of Surgery</u> 149:187-193 (1985) |
| 78 | Schena et al., "Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes" <u>Proc. Natl. Acad. Sci.</u> 93:10614-10619 (1996) |
| 79 | Selaru et al., "Global gene expression profiling in Barrett's esophagus and esophageal cancer: a comparative analysis using cDNA microarrays" <u>Oncogene</u> 21:475-478 (2002) |

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P2000R1Serial No.
10/712,124

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant
Victoria SmithFiling Date
13 Nov 2003Group
1645

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- | | |
|----|---|
| 80 | Shaheen et al., "Is There Publication Bias in the Reporting of Cancer Risk in Barrett's Esophagus?" <u>Gastroenterology</u> 119:333-338 (2000) |
| 81 | Skowron et al., "Human Brush Border Myosin-I and Myosin-Ic Expression in Human Intestine and Caco-2BBE Cells" <u>Cell Motility and the Cytoskeleton</u> 41:308-324 (1998) |
| 82 | Spechler et al., "Long-term Outcome of Medical and Surgical Therapies for Gastroesophageal Reflux Disease" <u>Journal of the American Medical Assn.</u> 285:2331-2338 (2001) |
| 83 | Stella and Himmelstein, "Prodrugs: A Chemical Approach to Targeted Drug Delivery" <u>Directed Drug Delivery</u> , Borchardt et al., Humana Press pps. 247-267 (1985) |
| 84 | Streitz et al., "Adenocarcinoma in Barrett's Esophagus" <u>Ann. Surg.</u> 213:122-125 (1991) |
| 85 | Tanaka et al., "Selective expression of liver and activation-regulated chemokine (LARC) in intestinal epithelium in mice and humans" <u>European Journal of Immunology</u> 29:633-642 (1999) |
| 86 | Tetsu & McCormick, " β -Catenin regulates expression of cyclin D1 in colon carcinoma cells" <u>Nature</u> 398:422-426 (1999) |
| 87 | Thompson & Weigel, "hAG-2, the Human Homologue of the Xenopus laevis Cement Gland Gene XAG-2, Is Coexpressed with Estrogen Receptor in Breast Cancer Cell Lines" <u>Biochem. & Biophys. Res. Comm.</u> 251:111-116 (1998) |
| 88 | Tice et al., "Synergistic Induction of Tumor Antigens by Wnt-1 Signaling and Retinoic Acid Revealed by Gene Expression Profiling" <u>Journal of Biological Chemistry</u> 277:14329-14335 (2002) |
| 89 | Tsujii et al., "Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells" <u>Cell</u> 93:705-716 (1998) |
| 90 | Tsujii et al., "Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential" <u>Proc. Natl. Acad. Sci. USA</u> 94:3336-3340 (1997) |
| 91 | Van Gelder et al., "Amplified RNA synthesized from limited quantities of heterogeneous cDNA" <u>Proc. Natl. Acad. Sci. USA</u> 87:1663-1667 (1990) |
| 92 | Visser et al., "Involvement of Cancer-activating Genes on Chromosomes 7 and 8 in Esophageal (Barrett's) and Gastric Cardia Adenocarcinoma" <u>Anticancer Res.</u> 21:3813-3820 (2001) |
| 93 | von Heijne, G., "A new method for predicting signal sequence cleavage sites" <u>Nucleic Acids Research</u> 14:4683-4690 (1986) |
| 94 | Walch et al., "Chromosomal Imbalances in Barrett's Adenocarcinoma and the Metaplasia-Dysplasia-Carcinoma Sequence" <u>American Journal of Pathology</u> 156:555-566 (2000) |
| 95 | Willert et al., "A transcriptional response to Wnt protein in human embryonic carcinoma cells" <u>BMC Developmental Biology</u> 2:1-7 (2002) |
| 96 | Wilman, D.E., "Prodrugs in Cancer Chemotherapy" <u>Biochemical Society Transactions</u> (615th Meeting, Belfast) 14:375-382 (1986) |
| 97 | Winters et al., "Barrett's Esophagus: A Prevalent, Occult Complication of Gastroesophageal Reflux Disease" <u>Gastroenterology</u> 92:118-124 (1987) |
| 98 | Wong et al., "p16 ^{INK4a} Lesions Are Common, Early Abnormalities that Undergo Clonal Expansion in Barrett's Metaplastic Epithelium" <u>Cancer Research</u> 61:8284-8289 (2001) |
| 99 | Wu et al., "Molecular Cloning and Expression of CYP2J2, a Human Cytochrome P450 Arachidonic Acid Epoxidase Highly Expressed in Heart" <u>Journal of Biological Chemistry</u> 271:3460-3468 (1996) |

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

